Jove
Visualize
Contact Us

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

491
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
491
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

7.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.3K
The Tumor Microenvironment02:17

The Tumor Microenvironment

6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Pyroptosis-associated Genes And Tumor Immune Response In Endometrial Cancer.
  1. Home
  3. Pyroptosis-associated Genes And Tumor Immune Response In Endometrial Cancer.

Related Experiment Video

Author Spotlight: Advancing Reproductive Immunology with a Protocol for the Quantitative Evaluation of Endometrial Immune Cells
07:46

Author Spotlight: Advancing Reproductive Immunology with a Protocol for the Quantitative Evaluation of Endometrial Immune Cells

Published on: October 13, 2023

1.2K

Pyroptosis-associated genes and tumor immune response in endometrial cancer.

Xiaodi Gong1, Zhifeng Wang2, Jiahao You2

  • 1Department of Gynecology and Obstetrics, The Second Affiliated Hospital of Naval Medical University, Shanghai, 200003, China. gong_xdi@sina.com.

Discover Oncology
|September 12, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

Pyroptosis-associated genes (PRGs) influence endometrial cancer (EC) progression. Specific PRGs like NOD2 and GPX4 impact survival and treatment response, aiding in developing a novel prognostic model for EC patients.

Keywords:
Endometrial cancerImmunotherapyNOD2Prognostic modelPyroptosis-related gene

More Related Videos

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.6K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.5K

Related Experiment Videos

Author Spotlight: Advancing Reproductive Immunology with a Protocol for the Quantitative Evaluation of Endometrial Immune Cells
07:46

Author Spotlight: Advancing Reproductive Immunology with a Protocol for the Quantitative Evaluation of Endometrial Immune Cells

Published on: October 13, 2023

1.2K
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.6K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.5K

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Pyroptosis, a programmed cell death, is implicated in tumor occurrence and progression.
  • The specific roles of pyroptosis-associated genes (PRGs) in endometrial cancer (EC) are not fully understood.
  • Identifying key PRGs can offer insights into EC pathogenesis and treatment strategies.

Purpose of the Study:

  • To investigate the expression patterns and prognostic significance of 29 PRGs in endometrial cancer (EC).
  • To explore the association between PRGs, patient survival, and response to therapies like chemotherapy and immune checkpoint blockade.
  • To develop a predictive model for EC prognosis based on PRG expression.

Main Methods:

  • Bioinformatic analysis of PRG expression in EC datasets.
  • Survival analysis (overall survival, progression-free survival) correlated with PRG levels.
  • Prognostic model construction using techniques like LASSO regression.
  • Correlation analysis with tumor microenvironment factors, including immune cell infiltration, TMB, MSI, and macrophage phenotypes.

    • Main Results:

    • 29 PRGs were found to be differentially expressed in EC.
    • Higher GPX4 and NOD2, and lower CASP6, PRKACA, NLRP2 expression correlated with better overall survival.
    • Lower NOD2 expression was linked to poorer progression-free survival and advanced tumor stage.
    • NOD2, NLRP2, and TNM stage were independent prognostic factors.
    • A LASSO model showed decreased OS in high-risk EC patients (ROC-AUC: 0.799).
    • NOD2 expression positively correlated with immune cell infiltration and immune checkpoints.
    • GPX4 and CASP6 associated with Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI).
    • Upregulated NOD2 in EC tissues correlated with advanced TNM stage and M1 macrophage infiltration.

    Conclusions:

    • PRGs play a significant role in EC progression and patient outcomes.
    • A PRG-based prognostic model, particularly incorporating NOD2, can predict EC patient survival.
    • NOD2-mediated pyroptosis may modulate tumor immunity and M1 macrophage polarization, impacting EC progression.